Ertugliflozin
Based on 5 publication(s) in Google Scholar
Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2. Has the potential for the treatment of type 2 diabetes mellitus.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.96%
- CAS. Nr.: 1210344-57-2
- Formel: C22H25ClO7
- Molecular Weight:436.88
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-10450
DapagliflozinSGLT2 Inhibitor -
HY-15409
EmpagliflozinSGLT2 Inhibitor -
HY-10451
CanagliflozinSGLT2 Inhibitor -
HY-15516
SotagliflozinSGLT Inhibitor -
HY-14894
IpragliflozinSGLT Inhibitor -
HY-13413
Tofogliflozin hydrateSGLT2 Inhibitor -
HY-15461R
Ertugliflozin (Standard)SGLT2 Inhibitor -
HY-15461A
Ertugliflozin L-pyroglutamic acidSGLT2 Inhibitor -
HY-15409R
Empagliflozin (Standard)SGLT2 Inhibitor -
HY-10450R
Dapagliflozin (Standard)SGLT2 Inhibitor -
HY-N0142
PhloretinAnti-inflammatory Agent -
HY-N0148
RutinCBR1 Inhibitor
Publications Citing Use of MedChemExpress (MCE) Ertugliflozin
More
Biologische Aktivität
Beschreibung
IC50 & Target
|
SGLT2 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
0.877 nM
Compound: 4, PF-04971729
|
Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of methyl alpha-D-glucopyranoside uptake after 1 hr
Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of methyl alpha-D-glucopyranoside uptake after 1 hr
|
[PMID: 21449606] |
| CHO | IC50 |
1960 nM
Compound: 4, PF-04971729
|
Inhibition of human SGLT1 expressed in CHO cells assessed as inhibition of methyl alpha-D-glucopyranoside uptake after 1 hr
Inhibition of human SGLT1 expressed in CHO cells assessed as inhibition of methyl alpha-D-glucopyranoside uptake after 1 hr
|
[PMID: 21449606] |
In Vitro
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 1210344-57-2
-
Appearance Solid
-
Molecular Weight 436.88
-
Formel C22H25ClO7
-
Color White to off-white
-
SMILES
ClC1=CC=C([C@]23O[C@@](CO)(CO3)[C@@H](O)[C@H](O)[C@H]2O)C=C1CC4=CC=C(OCC)C=C4
-
Synonyms
PF-04971729
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
-
Biochim Biophys Acta Mol Basis Dis
Ertugliflozin attenuates atherosclerosis in nondiabetic ApoE-/- mice by upregulating ABCA1 and LDLR via the PPARγ/LXRα pathway. [Abstract]2025 Oct;1871(7):167927. PMID: 40419168 -
Brain Commun
Ertugliflozin improves animal behaviours associated with oxidative stress and inflammation in a BTBR T + Itpr3tf/J mouse model of autism. [Abstract]2026 Mar 11;8(2):fcag083. PMID: 41907315 -
Am J Nephrol
Ertugliflozin Mitigates Renal Ischemia-Reperfusion Injury through the Downregulation of HIF-1α Expression. [Abstract]2025 Jul 24:1-21. PMID: 40706563 -
Biomed Pharmacother
Xelaglifam, a novel GPR40/FFAR1 agonist, exhibits enhanced β-arrestin recruitment and sustained glycemic control for type 2 diabetes. [Abstract]2024 Aug:177:117044. PMID: 38941892
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 250 mg/mL (572.24 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.76 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.76 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (274 KB)
-
SDS (719 KB)
- English - EN (719 KB)
- Français - FR (719 KB)
- Deutsch - DE (719 KB)
- Norwegian - NO (719 KB)
- Español - ES (719 KB)
- Swedish - SV (719 KB)
- Italian - IT (719 KB)
- Korean - KR (719 KB)
- Portuguese - PT (719 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Mascitti V, et al. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem. 2011 Apr 28;54(8):2952-60. [Content Brief]
[2]. Miao Z, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013 Feb;41(2):445-56. [Content Brief]
[3]. Kalgutkar AS, et al. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Drug Metab Dispos. 2011 Sep;39(9):1609-19. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2890 mL | 11.4448 mL | 22.8896 mL | 57.2240 mL |
| 5 mM | 0.4578 mL | 2.2890 mL | 4.5779 mL | 11.4448 mL | |
| 10 mM | 0.2289 mL | 1.1445 mL | 2.2890 mL | 5.7224 mL | |
| 15 mM | 0.1526 mL | 0.7630 mL | 1.5260 mL | 3.8149 mL | |
| 20 mM | 0.1144 mL | 0.5722 mL | 1.1445 mL | 2.8612 mL | |
| 25 mM | 0.0916 mL | 0.4578 mL | 0.9156 mL | 2.2890 mL | |
| 30 mM | 0.0763 mL | 0.3815 mL | 0.7630 mL | 1.9075 mL | |
| 40 mM | 0.0572 mL | 0.2861 mL | 0.5722 mL | 1.4306 mL | |
| 50 mM | 0.0458 mL | 0.2289 mL | 0.4578 mL | 1.1445 mL | |
| 60 mM | 0.0381 mL | 0.1907 mL | 0.3815 mL | 0.9537 mL | |
| 80 mM | 0.0286 mL | 0.1431 mL | 0.2861 mL | 0.7153 mL | |
| 100 mM | 0.0229 mL | 0.1144 mL | 0.2289 mL | 0.5722 mL |
Ertugliflozin Related Classifications
HY-15461 Related Classifications
Powered by Bioz